Functional transition: Inconsistently parallel to the increase in future liver remnant volume after preoperative portal vein embolization

Table 3 Comparison of the background factors between the functional future liver remnant volume superior group and future liver remnant volume superior group

	FFLRV superior group (n = 30)	FLRV superior group (n = 3)
Age (yr), mean ± SD	67.4 ± 9.1	69.7 ± 9.5
Gender
Male, n (%)	18 (60.0)	2 (66.7)
Female, n (%)	12 (40.0)	1 (33.3)
Body mass index (kg/m2), mean ± SD	21.8 ± 3.5	23.4 ± 7.0
Comorbidity (n)	Diabetes (5), hypertension (3), dyslipidemia (1), COPD (1), alcoholism (1), angina (1), lacunar infarction (1)	Diabetes (1), fatty liver (1), alcoholism (1)
HBV/HCV infection (n)	3/1	0/1
Child-Pugh score, mean ± SD	5.4 ± 0.9	5.7 ± 0.6
ICGR15 (%), mean ± SD	10.4 ± 6.3	7.2 ± 2.0
Initial resection ratio (%), mean ± SD	64.3 ± 5.6	66.8 ± 4.4
Initial FLRV (mL), mean ± SD	405.4 ± 79.0	466.3 ± 73.2

Functional future liver remnant volume (FFLRV) superior group included the patients without FFLRV decrease below the future liver remnant volume (FLRV) at 2 wk after PVE. FLRV superior group included the patients with FFLRV decrease below the FLRV at 2 weeks after PVE. SD: Standard deviation; COPD: Chronic obstructive pulmonary disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ICGR₁₅: Indocyanine green retention at 15 min; FLRV: Future liver remnant volume; FFLRV: Functional future liver remnant volume.